Downregulation of MiR-588 is Associated with Tumor Progression and Unfavorable Prognosis in Patients with Osteosarcoma
Overview
Authors
Affiliations
Osteosarcoma (OS) is a primary malignant tumor characterized by a high metastatic potential and poor prognosis. The dysregulation of miR-588 has been demonstrated to serve crucial roles in the progression of numerous types of cancer. The present study aimed to investigate the expression and function of miR-588 in the development of OS. To do so, clinical samples were collected and analyzed, and in vitro experiments were conducted. A total of 104 patients with OS were recruited between 2012 and 2014. The expression of miR-588 was analyzed by reverse transcription quantitative PCR. The association between miR-588 expression and the clinicopathological characteristics and survival rate of patients with OS was evaluated. Furthermore, Cell Counting Kit-8 and Transwell assays were used to evaluate the effect of miR-588 on the proliferation and the migratory and invasive abilities of various OS cell lines. The results demonstrated that miR-588 expression in OS tissues and cells was significantly lower compared with normal tissues and cells. In addition, miR-588 expression was closely associated with the Musculoskeletal Tumor Society (MSTS) staging of patients with OS. miR-588 expression and MSTS staging were therefore considered as independent indicators for the prognosis of patients with OS. In addition, miR-588 downregulation significantly stimulated the proliferation and migratory and invasive abilities of OS cells. Taken together, these findings indicated that miR-588 may serve as an independent prognostic factor and tumor suppressor in OS.
Chen T, Zhang Z, Tian C, Feng Y, He X, Jiang L J Cell Commun Signal. 2024; 18(2):e12029.
PMID: 38946721 PMC: 11208123. DOI: 10.1002/ccs3.12029.
CircECE1 promotes osteosarcoma progression through regulating RAB3D by sponging miR-588.
Liang Z, Shi Y, Guan Z J Orthop Surg Res. 2023; 18(1):587.
PMID: 37559140 PMC: 10410784. DOI: 10.1186/s13018-023-04045-4.
Su X, Wang B, Zhang B, Pan S J Radiat Res. 2023; .
PMID: 37154623 PMC: 10214998. DOI: 10.1093/jrr/rrad033.
Shu X, Liu W, Liu H, Qi H, Wu C, Ran Y PeerJ. 2021; 9:e12115.
PMID: 34557357 PMC: 8420872. DOI: 10.7717/peerj.12115.